The group's principal activity is to develop biologics for the treatment of human and animal diseases. The group is currently focusing its research on human health indications for the use of low-dose orally administered natural human interferon alpha. This is particularly for the treatment of sjogren's syndrome, behcet's disease, fibromyalgia, idiopathic pulmonary fibrosis and oral warts in HIV+ patients. The group owns 18 patents relating to low-dose oral natural interferon alpha.
